Not currently recruiting at UCSD
Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Kenneth Kalunian, MD
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSD
- Kenneth Kalunian, MD
Research Interests - Innovative strategies for the treatment of patients with rheumatoid arthritis and other rheumatic diseases - Prognostic and predictive factors for outcomes in rheumatic diseases
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Equillium
- Links
- company website
- ID
- NCT04128579
- Phase
- Phase 1
- Study Type
- Interventional
- Last Updated